Avelumab and Merkel Cell Carcinoma: Prognosis and Treatment Considerations

From General Health to Occupational Exposure

The legacy of general health and science information has long emphasized broad wellness principles, disease prevention, and the communication of medical advances to diverse audiences. This foundational approach prioritized accessible knowledge about immune function, cancer biology, and therapeutic innovations, often framed within population-level health contexts. As the field evolved, the need to address specific, real-world exposures became increasingly apparent, particularly where occupational environments intersect with emerging treatment modalities. Within mass production settings, workers may encounter pharmaceutical compounds or their byproducts during manufacturing, handling, or disposal processes. Avelumab, a monoclonal antibody used in oncology, represents one such agent where occupational exposure warrants careful consideration. While general health resources historically focused on patient-centered outcomes, the transition to occupational health requires attention to potential risks for personnel involved in production. This shift moves from broad educational content to targeted surveillance of exposure pathways, including inhalation, dermal contact, or accidental inoculation. The concern centers on whether chronic low-level exposure in manufacturing environments could influence long-term health outcomes, such as the development of Merkel cell carcinoma. Thus, the legacy of general health communication now pivots to a focused occupational lens, emphasizing the need for monitoring and protective measures in industrial contexts where avelumab is produced.

Avelumab: Mechanism and Clinical Use in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/; https://pubmed.ncbi.nlm.nih.gov/33439294/). This approval marked avelumab as the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). The clinical basis for avelumab's approval in metastatic MCC came from the two-part, single-arm, phase II trial JAVELIN Merkel 200. In Part A of that study, confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). More broadly, immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Prognosis and Risk Considerations for Avelumab-Treated Patients

For patients who become refractory to avelumab, treatment options are limited. In Europe, approved systemic therapies for MCC are restricted to avelumab, leaving avelumab-refractory patients without efficient and safe standard alternatives (https://pubmed.ncbi.nlm.nih.gov/33439294/). However, retrospective studies have explored the use of combined ipilimumab plus nivolumab in this setting. In a multicenter study from Germany, three out of five patients with avelumab-refractory metastatic MCC responded to combined ipilimumab plus nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A separate retrospective study confirmed that immune checkpoint inhibitors, including avelumab, offer durable responses and significant clinical benefit for advanced MCC, with two agents—avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1)—currently approved by the U.S. Food and Drug Administration for this indication (https://pubmed.ncbi.nlm.nih.gov/35877101/). The prognosis for patients with MCC is influenced by the disease's aggressive nature and high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). MCC is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients treated with avelumab, the timeline between exposure and documented harm includes the potential for immune-related adverse events (irAEs). Checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to irAEs (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab; the hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates that while irAEs can occur during avelumab treatment, they may be manageable without necessitating discontinuation of therapy.

Adequacy of Warnings and Evidence Gaps

Regarding the adequacy of warnings about avelumab and MCC, the evidence indicates that avelumab is approved specifically for metastatic MCC, and its use is supported by clinical trial data showing objective responses in chemotherapy-refractory patients (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, the risk of progression remains substantial, with about half of patients not responding to initial immune checkpoint inhibitor therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For avelumab-refractory patients, the lack of approved alternative treatments in Europe underscores a gap in therapeutic options, though combined ipilimumab plus nivolumab has shown activity in small retrospective series (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). The prognosis for affected patients depends on response to therapy, with those who achieve objective responses experiencing clinical benefit, while those who progress face limited subsequent options. In summary, avelumab represents a key therapeutic advance for metastatic MCC, with evidence of efficacy in a subset of patients. However, the aggressive nature of MCC, the potential for irAEs, and the high rate of progression on therapy highlight important risk considerations. The timeline from exposure to harm includes both the immediate risk of irAEs and the longer-term risk of disease progression, which may occur despite treatment. For patients who become refractory, alternative immune checkpoint inhibitor combinations may offer some benefit, but data remain limited to small studies.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is avelumab and how does it work?

What is the prognosis for patients with Merkel cell carcinoma treated with avelumab?

The prognosis varies: about one-third of chemotherapy-refractory patients achieve objective responses with avelumab, but approximately 50% of patients with advanced MCC progress on immune checkpoint inhibitors (https://pubmed.ncbi.nlm.nih.gov/29799096/; https://pubmed.ncbi.nlm.nih.gov/35877101/). For those who become refractory, alternative treatments like combined ipilimumab plus nivolumab may offer benefit in some cases (https://pubmed.ncbi.nlm.nih.gov/33439294/).

What are the risks of immune-related adverse events with avelumab?

Checkpoint inhibitors, including avelumab, can cause overactivation of the immune system leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). These may be manageable with corticosteroids and do not always require discontinuation of therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.